NeuroSigma is aiming to net as much as $50.2 million in its upcoming IPO, as the UCLA spinout develops a noninvasive system to treat epilepsy that proves resistant to drug regimens.
NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout's noninvasive system to treat drug-resistant epilepsy.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1vxxl4z
Cap comentari:
Publica un comentari a l'entrada